Hi Deera Mahasin

Among cell therapy approaches, you could consider the adoptive T-cell therapy.

Adoptive T-cell therapy refers to the process where patients’ T lymphocytes are extracted and isolated from tumor or blood. They are then activated and expanded in vitro, some with genetic modification, then re-infused usually following lymphodepletion chemotherapy. Such therapies can exist in the form of autologous TIL infusion, chimeric antigen receptor T-cell (CAR-T) therapy targeting specific surface tumor antigens and genetically modified (GM) T-cell receptor (TCR) T-cell therapy.

For more information you may refer to the article attached below.

Article A Perspective on Cell Therapy and Cancer Vaccine in Biliary ...

Strategies to improve the clinical efficacy of a therapeutic adoptive T-cell therapy in Biliary Tract Cancers (BTCs) include discovery of personalized neoantigens to tailor greater personalized immunotherapy. Preclinical organoid or cell line models may be able to reveal key mutations and mediators that influence TIL infiltration or response to immunotherapy and can potentially aid in future cell therapy development.

Good Luck!

You're welcome Deera Mahasin